Innate Pharma (IPH) investor relations material

Strategic focus and organizational changes

• Refocused pipeline to three lead clinical assets: IPH4502, lacutamab, and monalizumab, following a mid-year strategic refresh.

• Downsized organization by 30% to prioritize funding for clinical programs over infrastructure.

• R&D efforts now centered on advancing next-generation ADCs.

Clinical development highlights

• Lacutamab received FDA breakthrough therapy designation for Sézary syndrome and is on an accelerated approval path, with a confirmatory phase III study greenlit.

• Phase II data for lacutamab showed a 42.9% objective response rate and over 25 months' response durability in Sézary syndrome post-mogamulizumab.

• Monalizumab, in partnership with AstraZeneca, is in a fully enrolled phase III PACIFIC-9 study for stage III non-resectable NSCLC, with primary completion expected June 2026.

• IPH4502, a differentiated Nectin-4 ADC, is in phase I with early signs of clinical activity and potential in PADCEV-resistant settings.

Differentiation and market potential

• IPH4502 targets a unique Nectin-4 epitope, enabling efficacy in low/moderate expressors and PADCEV-resistant tumors, with a novel exatecan payload and hydrophilic linker.

• Preclinical models show IPH4502 induces tumor regression where PADCEV fails, especially in low-expressing cancers like esophageal.

• Lacutamab's phase III will address both Sézary syndrome and mycosis fungoides, with potential to expand into early-stage CTCL and PTCL.